Repare Therapeutics Inc. (RPTX)
NMS – Real vaqt narxi. Valyuta: USD
2.65
0.00 (0.00%)
Yopilishda: Jan 27, 2026, 4:00 PM EDT

NMS – Real vaqt narxi. Valyuta: USD
2.65
0.00 (0.00%)
Yopilishda: Jan 27, 2026, 4:00 PM EDT
Repare Therapeutics Inc., klinik tadqiqot bosqichidagi aniq onkologiya kompaniyasi bo'lib, Shveytsariya va Qo'shma Shtatlarda terapevtik vositalarni kashf qilish va ishlab chiqish bilan shug'ullanadi. Kompaniya genetik beqarorlik mexanizmlari, shu jumladan DNK shikastlanishini tiklash tufayli yuzaga keladigan saraton kasalliklarini davolash uchun saraton terapiyalarini kashf qilish va ishlab chiqish uchun o'zining patentlangan, genoma-keng va CRISPR-ga asoslangan SNIPRx platformasidan foydalanadi. Shuningdek, u qattiq o'smalarni davolash uchun 1/2 fazali klinik sinovda bo'lgan Ataksiya-telangiektaziya va Rad3-related protein kinazaning kuchli va selektiv og'iz orqali qabul qilinadigan kichik molekulali inhibitori bo'lgan kamonsertib (RP-3500) va 1/2 fazali klinik sinovda bo'lgan Protein Kinaza Membrana bilan bog'liq tirozin- va treonin-spesifik cdc-2 inhibitör kinazaning selektiv va kuchli og'iz orqali qabul qilinadigan kichik molekulali inhibitori bo'lgan lunresertib (RP-6306)ni ishlab chiqadi. Bundan tashqari, kompaniya qattiq o'smalarda TRIM37 amplifikatsiyasi yoki ortiqcha ekspressiyasi bilan sinergik halokatli munosabatlarni ishga solish uchun 1-fazali klinik sinovda bo'lgan og'iz orqali qabul qilinadigan PLK4 ingibitori bo'lgan RP-1664 va 1-fazali klinik sinovda bo'lgan DNK polimeraza theta'ning gemikaza domenidagi adenosintrifosfataza faoliyatining ingibitori bo'lgan RP-3467ni ishlab chiqmoqda. Kompaniya Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd. va Nyu-York universiteti bilan strategik hamkorlikka ega. Repare Therapeutics Inc. 2016-yilda tashkil etilgan va shtab-kvartirasi Kanadaning Monreal shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Agnel Sfeir Ph.D. | Co-Founder |
| Dr. Daniel Durocher Ph.D. | Co-Founder |
| Dr. Frank Sicheri Ph.D. | Co-Founder |
| Dr. Joseph P. O'Connell M.D. | Executive Vice President of Clinical Development and Medical Affairs |
| Mr. Daniel Belanger | Executive Vice President of Human Resources |
| Mr. Steve Forte CPA | President, CFO, CEO & Director |
| Ms. Sandra Alves | Senior VP & Chief Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-28 | 8-K | d95398d8k.htm |
| 2026-01-16 | 8-K | d14040d8k.htm |
| 2025-12-29 | DEFA14A | d32279ddefa14a.htm |
| 2025-12-19 | DEFA14A | d59892ddefa14a.htm |
| 2025-12-15 | DEFM14A | d922114ddefm14a.htm |
| 2025-12-03 | PREM14A | d922114dprem14a.htm |
| 2025-11-20 | DEFA14A | d849215ddefa14a.htm |
| 2025-11-17 | DEFA14A | d920795ddefa14a.htm |
| 2025-11-14 | 10-Q | rptx-20250930.htm |
| 2025-10-22 | 8-K | rptx-20251022.htm |